Stockscreener 앱 받기
18.75
3.10%
-0.60
시간 외 거래:
16.63
-2.12
-11.31%
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Earnings call transcript: Castle Biosciences Q1 2025 revenue growth surpasses expectations - Investing.com Australia
Castle Biosciences (CSTL) to Acquire Gastrointestinal Firm Previse | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Adjusts 2025 Revenue Outlook | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Exceeds Revenue Expectations in Q1 | CSTL Stock News - GuruFocus
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Castle Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Castle Biosciences Reports 21% Revenue Increase in Q1 2025 - TipRanks
Castle Biosciences to buy Previse (CSTL:NASDAQ) - Seeking Alpha
Castle Biosciences To Acquire Previse - marketscreener.com
Castle Biosciences to Acquire Previse | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse for GI Test Expansion - Investing.com
Castle Biosciences Reports First Quarter 2025 Results | CSTL Stock News - GuruFocus
Castle Biosciences Reports First Quarter 2025 Results - GlobeNewswire
Castle Biosciences to Acquire Previse - GlobeNewswire
Castle Biosciences to Acquire Previse - Benzinga
Castle Biosciences Acquires Johns Hopkins-Backed GI Health Company Previse to Transform Cancer Detection - Stock Titan
Wells Fargo & Company MN Boosts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Barclays PLC Sells 3,288 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Invesco Ltd. Raises Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday - Defense World
New Data at DDW 2025 Further Demonstrates the TissueCypher® - GlobeNewswire
New Clinical Data Reveals How TissueCypher Test Could Transform Early Esophageal Cancer Detection - Stock Titan
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: W - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Ou - GuruFocus
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - GlobeNewswire
DecisionDx-Melanoma Test Achieves 97.2% Accuracy in Identifying Low-Risk Melanoma Patients - Stock Titan
Legal & General Group Plc Sells 6,356 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' DecisionDx-Melanoma Test Orders Reach 200,000 - marketscreener.com
Castle Biosciences (CSTL) Reaches Key Milestone with Melanoma Te - GuruFocus
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma - GlobeNewswire
Melanoma Diagnostic Breakthrough: DecisionDx Test Hits 200,000 Orders, Backed by 50+ Clinical Studies - Stock Titan
Envestnet Asset Management Inc. Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Russell Investments Group Ltd. Has $192,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Me - GuruFocus
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis - The Manila Times
Castle Biosciences to Present Research on Melanoma Patient Care at AACR Annual Meeting 2025 - Nasdaq
New Data at AACR Annual Meeting Highlights Use of - GlobeNewswire
Closing Figures Unveiled: Castle Biosciences Inc (CSTL) Drop -1.60, Closes at 20.93 - DWinneX
How did Castle Biosciences Inc (CSTL) fare last session? - uspostnews.com
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 3.9% After Insider Selling - Defense World
LPL Financial LLC Has $614,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Raised by Geode Capital Management LLC - Defense World
CSTL’s Stock Market Adventure: -19.29% YTD Growth Amidst Volatility - investchronicle.com
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)? - simplywall.st
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha
Castle Biosciences to Release First Quarter 2025 Financial Resul - GuruFocus
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Franklin Resources Inc. - Defense World
28,903 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Arrowstreet Capital Limited Partnership - Defense World
Vanguard Group Inc. Has $48.84 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Corebridge Financial Inc. Has $343,000 Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock By Investing.com - Investing.com Canada
KLP Kapitalforvaltning AS Buys New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock - Investing.com
Form DEF 14A CASTLE BIOSCIENCES INC For: May 22 - StreetInsider
SEC Form DEF 14A filed by Castle Biosciences Inc. - Quantisnow
American Century Companies Inc. Has $1.84 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences backs esophageal cancer awareness - Investing.com Australia
Castle Biosciences backs esophageal cancer awareness By Investing.com - Investing.com South Africa
0.34%
0.46%
자본화:
|
볼륨(24시간):